{"title":"Characterization and Therapeutic Assessment of Phytomediated Silver Nanoparticles Produced from the Stem Bark of Bombax ceiba.","authors":"Narendhar Dharavath, Mahendar Porika, Radhika Tippani, Anand Kishore Kola, Tomy Murigingayil Joseph, Maxim Shevtsov, Shirish H Sonawane","doi":"10.1055/a-2695-0339","DOIUrl":null,"url":null,"abstract":"<p><p>The study aims to develop an environmentally friendly method of producing silver nanoparticles using an extract from <i>Bombax ceiba</i> stem bark (<i>Bc</i>-AgNPs) and to investigate their potential medical applications, such as preventing blood cell damage, combating oxidation, and lowering inflammation. The synthesized <i>Bc</i>-AgNPs were characterized using UV-visible spectroscopy, X-ray diffraction (XRD), Fourier transform infrared spectroscopy, and transmission electron microscopy (TEM). The zeta potential examination revealed a highly stable colloidal solution of <i>Bc</i>-AgNPs with a surface charge of-14 mV. The synthesized <i>Bc</i>-AgNPs had a face-centred cubic structure with a crystalline size of 26 nm and an average grain size of 59.8 nm, as seen in the TEM images. <i>Bc</i>-AgNPs showed no hemolysis at varied concentrations, but <i>B. ceiba</i> stem bark extract at 100 µg/mL caused 16.8±1.9% hemolysis, and Triton X-100 (0.1%; positive control) caused 99.1±0.4% hemolysis. <i>B. ceiba</i>'s aqueous extract contained flavonoid and phenolic components, which enhanced <i>Bc</i>-AgNPs' antioxidant capacity. The relative IC50 values were 28.03±0.98 µg/mL and 33.7±0.38 µg/mL. When compared to a reference medication, <i>Bc</i>-AgNPs demonstrated a moderate antiinflammatory effect, with IC50 values of 42.26±0.74 µg/mL for BSA and 50.93±1.07 µg/mL for egg albumin assay. According to the study, bio/hemocompatible <i>Bc</i>-AgNPs may be a viable treatment choice for antiinflammatory and antioxidant treatments.</p>","PeriodicalId":11451,"journal":{"name":"Drug Research","volume":" ","pages":""},"PeriodicalIF":2.1000,"publicationDate":"2025-09-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Drug Research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1055/a-2695-0339","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0
Abstract
The study aims to develop an environmentally friendly method of producing silver nanoparticles using an extract from Bombax ceiba stem bark (Bc-AgNPs) and to investigate their potential medical applications, such as preventing blood cell damage, combating oxidation, and lowering inflammation. The synthesized Bc-AgNPs were characterized using UV-visible spectroscopy, X-ray diffraction (XRD), Fourier transform infrared spectroscopy, and transmission electron microscopy (TEM). The zeta potential examination revealed a highly stable colloidal solution of Bc-AgNPs with a surface charge of-14 mV. The synthesized Bc-AgNPs had a face-centred cubic structure with a crystalline size of 26 nm and an average grain size of 59.8 nm, as seen in the TEM images. Bc-AgNPs showed no hemolysis at varied concentrations, but B. ceiba stem bark extract at 100 µg/mL caused 16.8±1.9% hemolysis, and Triton X-100 (0.1%; positive control) caused 99.1±0.4% hemolysis. B. ceiba's aqueous extract contained flavonoid and phenolic components, which enhanced Bc-AgNPs' antioxidant capacity. The relative IC50 values were 28.03±0.98 µg/mL and 33.7±0.38 µg/mL. When compared to a reference medication, Bc-AgNPs demonstrated a moderate antiinflammatory effect, with IC50 values of 42.26±0.74 µg/mL for BSA and 50.93±1.07 µg/mL for egg albumin assay. According to the study, bio/hemocompatible Bc-AgNPs may be a viable treatment choice for antiinflammatory and antioxidant treatments.
期刊介绍:
Drug Research (formerly Arzneimittelforschung) is an international peer-reviewed journal with expedited processing times presenting the very latest research results related to novel and established drug molecules and the evaluation of new drug development. A key focus of the publication is translational medicine and the application of biological discoveries in the development of drugs for use in the clinical environment. Articles and experimental data from across the field of drug research address not only the issue of drug discovery, but also the mathematical and statistical methods for evaluating results from industrial investigations and clinical trials. Publishing twelve times a year, Drug Research includes original research articles as well as reviews, commentaries and short communications in the following areas: analytics applied to clinical trials chemistry and biochemistry clinical and experimental pharmacology drug interactions efficacy testing pharmacodynamics pharmacokinetics teratology toxicology.